IGF1R and hepatocellular carcinoma: Furthermore, sorafenib-treated HCC patients with negative IGF1R expression showed significantly better OS (HR=4.96; 95%CI: 2.69 to 9.14; P<0.0001) and DFS (HR=2.63; 95%CI: 1.49 to 4.61; P<0.0001) than those with high IGF1R expression (Figure 3H).